Emcure Pharmaceuticals is currently trading at Rs. 1374.70, up by 10.85 points or 0.80% from its previous closing of Rs. 1363.85 on the BSE.

The scrip opened at Rs. 1394.00 and has touched a high and low of Rs. 1395.00 and Rs. 1369.00 respectively. So far 4661 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 10 has touched a 52 week high of Rs. 1577.50 on 18-Sep-2024 and a 52 week low of Rs. 890.00 on 07-Apr-2025.

Last one week high and low of the scrip stood at Rs. 1395.00 and Rs. 1284.40 respectively. The current market cap of the company is Rs. 26346.40 crore.

The promoters holding in the company stood at 77.92%, while Institutions and Non-Institutions held 6.51% and 15.57% respectively.

Emcure Pharmaceuticals (Emcure) and Sanofi India (SIL) have entered into an exclusive distribution and promotion agreement for SIL’s oral anti-diabetic (OAD) products in India, effective immediately. Emcure will exclusively distribute and promote the company’s OAD range of products that include well-established brands like Amaryl and Cetapin. 

While SIL will continue to own and manufacture these brands across Sanofi’s plants in India and internationally, Emcure will leverage its strengths to engage healthcare professionals and expand reach of these therapeutic solutions for patients who need them across all of India. There will be no people transition from SIL to Emcure in this arrangement.

Emcure Pharmaceuticals is one of the leading Indian pharmaceutical companies engaged in developing, manufacturing and globally marketing a broad range of pharmaceutical products across several major therapeutic areas.